Cardiovascular Drugs Practice Questions

Q: Which of the following drugs acts as a direct vasodilator on blood vessels?

Hydralazine. ***Hydralazine*** - **Hydralazine** is a **direct-acting vasodilator** that works by directly relaxing the smooth muscle of **arterioles**. - Unlike drugs that work through receptors or central mechanisms, hydralazine acts **directly on vascular smooth muscle** to cause relaxation. - This direct relaxation leads to a decrease in **peripheral vascular resistance**, which lowers blood pressure. - It is a prototype drug for understanding direct vasodilator mechanisms. *Verapamil* - **Verapamil** is a **non-dihydropyridine calcium channel blocker** that works by blocking L-type calcium channels. - Its vasodilatory effects are **indirect**, mediated through calcium channel blockade rather than direct smooth muscle relaxation. - Its main actions are to reduce **heart rate** and **myocardial contractility**, with secondary vasodilation. *Propranolol* - **Propranolol** is a **non-selective beta-blocker** that primarily reduces blood pressure by decreasing heart rate and myocardial contractility. - Its effects on blood vessels are **indirect**, mainly by blocking **beta-1 receptors** in the heart and **beta-2 receptors** in the vasculature. - It is not a direct vasodilator and may even cause vasoconstriction due to unopposed alpha-adrenergic effects. *Methyldopa* - **Methyldopa** is an **alpha-2 adrenergic agonist** that acts **centrally** in the brainstem to reduce sympathetic outflow. - It does not directly act on blood vessels but rather reduces peripheral vascular tone through its **central nervous system effects**. - Its mechanism is indirect, working through the CNS rather than peripheral vascular tissue.

Q: Which of the following is the traditional first-line drug used for closure of patent ductus arteriosus?

Indomethacin. ***Indomethacin*** - This **prostaglandin synthesis inhibitor** is traditionally the first-line medication used to promote closure of a **patent ductus arteriosus (PDA)** in preterm infants. - It works by inhibiting **cyclooxygenase (COX) enzymes**, thereby reducing prostaglandin E2 (PGE2) levels, which are critical for maintaining ductal patency. *Paracetamol* - While sometimes used as an alternative, **paracetamol (acetaminophen)** is not the traditional first-line drug for PDA closure. - It has a weaker effect on prostaglandin synthesis compared to NSAIDs like indomethacin. *Alprostadil* - **Alprostadil (prostaglandin E1)** is used to **maintain** the patency of the ductus arteriosus in infants with severe congenital heart defects that require a patent ductus for systemic or pulmonary blood flow. - It works in direct opposition to the goal of PDA closure. *Celecoxib* - **Celecoxib** is a **selective COX-2 inhibitor** and is not typically used for PDA closure. - Its efficacy and safety profile for this specific indication have not been established as widely as indomethacin.

Q: In the context of bilateral renal artery stenosis, which antihypertensive drug is considered contraindicated?

ACE inhibitors. ***ACE inhibitors*** - In bilateral renal artery stenosis, ACE inhibitors can precipitate **acute kidney injury** by severely reducing **glomerular filtration pressure**, as both kidneys rely on **angiotensin II** for maintaining this pressure [1]. - They inhibit the production of **angiotensin II**, leading to **efferent arteriolar dilation** and a drop in glomerular hydrostatic pressure, which is critical for filtration in stenosed kidneys [2]. *Beta-blockers* - Beta-blockers are generally considered safe and effective in treating hypertension associated with renal artery stenosis, as they do not directly interfere with **renal autoregulation** in the same critical way as ACE inhibitors. - They lower blood pressure by reducing **cardiac output** and inhibiting renin release but do not acutely compromise **glomerular filtration** in the presence of stenosis. *Calcium channel blockers* - Calcium channel blockers are safe to use in bilateral renal artery stenosis and are often effective in controlling blood pressure. - They dilate **afferent arterioles**, which can actually help maintain or improve **glomerular filtration rate** by increasing blood flow to the glomerulus. *Diuretics* - Diuretics can be used cautiously in renal artery stenosis to manage blood pressure and fluid overload. - However, aggressive diuresis can lead to intravascular volume depletion, which might exacerbate **renal hypoperfusion** in already stenosed kidneys.

Q: What is the drug with the highest efficacy to increase plasma HDL?

Nicotinic acid (Niacin). ***Nicotinic acid (Niacin)*** - Niacin has the **highest efficacy** among lipid-lowering drugs in increasing **plasma HDL cholesterol** levels, often by 15-35%. - It works by reducing the **hepatic synthesis of VLDL** (and thus LDL) as well as increasing the half-life of HDL. *Ezetimibe (Zetia)* - Ezetimibe primarily acts by inhibiting the **absorption of cholesterol** from the intestine. - While it lowers LDL cholesterol, its effect on **increasing HDL** is modest at best, typically in the single digits. *Gemfibrozil (Lopid)* - Gemfibrozil is a **fibrate** that is best known for significantly lowering **triglycerides** and increasing HDL cholesterol modestly. - Its effects on HDL are generally **less robust** than those of niacin, usually in the range of 10-20%. *Rosuvastatin (Crestor)* - Rosuvastatin is a **statin**, which primarily works by inhibiting **HMG-CoA reductase**, leading to a significant reduction in LDL cholesterol. - While statins can cause a small increase in HDL, typically about 5-10%, this effect is **not its primary mechanism** of benefit nor its greatest strength compared to niacin.

Q: Drug not used in pulmonary hypertension is:

Alpha blocker. ***Alpha blocker*** - Alpha-blockers primarily cause **systemic vasodilation** [1] and are not indicated for the specific pulmonary vascular remodeling and vasoconstriction seen in pulmonary hypertension. [2] - Their use could lead to an undesirable drop in **systemic blood pressure** [3] without adequately addressing the pulmonary arterial pressure. *Calcium channel blocker* - **Calcium channel blockers** (namely **dihydropyridines** like nifedipine and amlodipine) are used in a small subset of pulmonary hypertension patients who are **vasoreactive** on acute testing. - They work by relaxing pulmonary arterial smooth muscle, reducing **pulmonary vascular resistance**. *Endothelin receptor antagonist* - **Endothelin receptor antagonists** (e.g., bosentan, ambrisentan) block the effects of **endothelin-1**, a potent vasoconstrictor and smooth muscle proliferator involved in pulmonary hypertension. - They improve hemodynamics, exercise capacity, and clinical outcomes by preventing **vasoconstriction** and **vascular remodeling**. *Prostacyclin* - **Prostacyclin analogs** (e.g., epoprostenol, treprostinil) are potent **vasodilators** and inhibitors of platelet aggregation. - They are highly effective in treating severe pulmonary hypertension by relaxing pulmonary arteries and preventing **thrombosis**.

Q: Digitalis acts in atrial fibrillation by

Increasing AV node refractoriness. ***Increasing AV node refractoriness*** - **Digitalis** (digoxin) primarily works in atrial fibrillation by **increasing the refractoriness** of the **AV node** through enhanced **vagal tone**. - This action slows the conduction of electrical impulses from the atria to the ventricles, thereby controlling the **ventricular rate** - which is the therapeutic goal in AF. - This is the **clinical mechanism** by which digitalis treats atrial fibrillation. *Decreasing atrial contractility* - Digitalis has **positive inotropic effects** (increases contractility), not negative. - It increases both atrial and ventricular contractility through increased intracellular calcium. - This option is incorrect as it contradicts the fundamental action of digitalis. *Inhibiting Na+ K+ ATPase pump* - While this is the **molecular mechanism** of digitalis at the cellular level, it is not the direct answer to how digitalis "acts in atrial fibrillation." - Na+/K+ ATPase inhibition → increased intracellular Na+ → decreased Na+/Ca2+ exchange → increased intracellular Ca2+ → positive inotropy. - The question asks about the **therapeutic action in AF**, which is controlling ventricular rate through AV nodal effects, not the underlying molecular mechanism. - This is a common distractor - students must distinguish between molecular mechanism and clinical therapeutic action. *Inhibiting Na+ H+ ATPase pump* - Digitalis **does not inhibit the Na+/H+ exchanger**. - This pump is primarily involved in **pH regulation** and is not a target of cardiac glycosides. - This option is completely incorrect.

Q: Which of the following is a contraindication for the use of digitalis?

WPW Syndrome. ***WPW Syndrome*** - In **WPW syndrome**, digitalis can **accelerate conduction** through the accessory pathway, leading to a rapid and potentially life-threatening ventricular response, especially during **atrial fibrillation**. - This can trigger **ventricular tachycardia** or **ventricular fibrillation** in patients with pre-excitation. - This is an **absolute contraindication** to digitalis use. *Acute rheumatic carditis* - Acute rheumatic carditis is a **relative contraindication** to digitalis due to increased risk of **digitalis toxicity** in inflamed myocardium. - The inflamed heart muscle is more **sensitive to arrhythmogenic effects** of digitalis. - However, **WPW syndrome is a more absolute contraindication** as the mechanism of harm is more predictable and severe. - If heart failure is present, digitalis may be used with **extreme caution** under close monitoring. *Thyrotoxicosis* - While digitalis may be used cautiously in patients with thyrotoxicosis experiencing **tachyarrhythmias** or heart failure, it's not an absolute contraindication. - Digitalis effectiveness is **reduced in hyperthyroid states**, often requiring higher doses. - The primary treatment for thyrotoxicosis is to manage the **hyperthyroid state**, which often resolves the cardiac symptoms. *Atrial fibrillation with rapid ventricular response* - Digitalis is often used to **slow the ventricular rate** in atrial fibrillation with a rapid ventricular response by **increasing vagal tone** and inhibiting the AV node. - This is a common **indication** for digitalis therapy, not a contraindication.

Q: Hyperkalemia is associated with:

Angiotensin-converting enzyme (ACE) inhibitors. ***Angiotensin-converting enzyme (ACE) inhibitors*** - **ACE inhibitors** block the conversion of **angiotensin I to angiotensin II**, which reduces **aldosterone** secretion. - Reduced **aldosterone** leads to decreased **potassium excretion** in the kidneys, causing **potassium retention** and potentially **hyperkalemia**. - This is a well-known adverse effect, especially in patients with **renal impairment** or when combined with **potassium-sparing diuretics** or **potassium supplements**. *Thiazide diuretics (e.g., Chlorthalidone)* - **Thiazide diuretics** work by inhibiting the **sodium-chloride cotransporter** in the **distal convoluted tubule**, increasing sodium and water excretion. - This action typically leads to **hypokalemia** by increasing **potassium excretion**, not hyperkalemia. *Loop diuretics (e.g., Furosemide)* - **Loop diuretics** inhibit the **Na-K-2Cl cotransporter** in the **thick ascending limb of the loop of Henle**. - They are potent **potassium-wasting diuretics** that cause **hypokalemia** through increased renal potassium excretion, not hyperkalemia. *Antiarrhythmic agents (e.g., Amiodarone)* - **Amiodarone** is an antiarrhythmic agent that primarily acts by blocking **potassium channels** and has complex electrophysiological effects. - It is not directly associated with causing **hyperkalemia**; its primary electrolyte-related side effects involve thyroid function, not potassium homeostasis.

Q: Which of the following is the most effective medication for reducing proteinuria in diabetic patients?

Perindopril. ***Perindopril*** - **Perindopril** is an **ACE inhibitor**, which are cornerstone drugs for reducing **proteinuria** in diabetic patients by lowering intraglomerular pressure and reducing glomerular hyperfiltration. - ACE inhibitors like perindopril have been shown to slow the progression of **diabetic nephropathy** and improve renal outcomes beyond just their antihypertensive effects. *Chlorthalidone* - **Chlorthalidone** is a **thiazide-type diuretic** primarily used for hypertension management and edema. - While it lowers blood pressure, it does not have the specific renoprotective effects on **proteinuria** that ACE inhibitors possess in diabetic nephropathy. *Clonidine* - **Clonidine** is a **central alpha-2 adrenergic agonist** used for hypertension, but it does not specifically target the mechanisms of proteinuria. - It works by reducing sympathetic outflow from the central nervous system, which is distinct from the renal hemodynamic effects of ACE inhibitors. *Metoprolol* - **Metoprolol** is a **beta-blocker** primarily used for hypertension and cardiovascular conditions. - While it reduces blood pressure, it does not offer the same degree of proteinuria reduction or renoprotective benefits in diabetic nephropathy as ACE inhibitors.

Question 1

Which of the following drugs acts as a direct vasodilator on blood vessels?

Accepted Answer

Hydralazine

Answer

Verapamil

Answer

Propranolol

Answer

Methyldopa

Question 2

Which of the following is the traditional first-line drug used for closure of patent ductus arteriosus?

Accepted Answer

Indomethacin

Answer

Paracetamol

Answer

Alprostadil

Answer

Celecoxib

Question 3

In the context of bilateral renal artery stenosis, which antihypertensive drug is considered contraindicated?

Accepted Answer

ACE inhibitors

Answer

Beta-blockers

Answer

Calcium channel blockers

Answer

Diuretics

Question 4

What is the mechanism of action of Verapamil?

Accepted Answer

Inhibition of calcium ion influx through L-type calcium channels

Answer

Blocking membrane depolarisation

Answer

Stabilization of cardiac membrane potential

Answer

Inhibition of calcium-dependent action potentials

Question 5

What is the drug with the highest efficacy to increase plasma HDL?

Accepted Answer

Nicotinic acid (Niacin)

Answer

Ezetimibe (Zetia)

Answer

Gemfibrozil (Lopid)

Answer

Rosuvastatin (Crestor)

Question 6

Drug not used in pulmonary hypertension is:

Accepted Answer

Alpha blocker

Answer

Endothelin receptor antagonist

Answer

Prostacyclin

Answer

Calcium channel blocker

Question 7

Digitalis acts in atrial fibrillation by

Accepted Answer

Increasing AV node refractoriness

Answer

Decreasing atrial contractility

Answer

Inhibiting Na+ K+ ATPase pump

Answer

Inhibiting Na+ H+ ATPase pump

Question 8

Which of the following is a contraindication for the use of digitalis?

Accepted Answer

WPW Syndrome

Answer

Thyrotoxicosis

Answer

Acute rheumatic carditis

Answer

Atrial fibrillation with rapid ventricular response

Question 9

Hyperkalemia is associated with:

Accepted Answer

Angiotensin-converting enzyme (ACE) inhibitors

Answer

Thiazide diuretics (e.g., Chlorthalidone)

Answer

Antiarrhythmic agents (e.g., Amiodarone)

Answer

Loop diuretics (e.g., Furosemide)

Question 10

Which of the following is the most effective medication for reducing proteinuria in diabetic patients?

Accepted Answer

Perindopril

Answer

Clonidine

Answer

Chlorthalidone

Answer

Metoprolol

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?